Dr. Ramalingam on Updated Data With Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

Suresh S. Ramalingam, MD, FASCO

Suresh S. Ramalingam, MD, FASCO, discusses updated data with mobocertinib in EGFR exon 20 insertion–positive advanced non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, deputy director, director, Lung Cancer Program, Winship Cancer Institute of Emory University, professor, assistant dean, Roberto C. Goizueta Distinguished Chair for Cancer Research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses updated data with mobocertinib in EGFR exon 20 insertion–positive advanced non–small cell lung cancer (NSCLC).

A phase 1/2 trial (NCT02716116) evaluated mobocertinib in patients with EGFR exon 20 insertion–mutated metastatic NSCLC who had received at least 1 prior line of therapy for locally advanced or metastatic disease. Patients received mobocertinib at a dose of 160 mg once daily. 

The updated data, which were presented during the 2021 ASCO Annual Meeting, indicated an objective response rate of 28% and a median duration of response of 17.5 months in platinum-pretreated patients. These results indicate that mobocertinib could represent an effective agent for patients with EGFR exon 20 insertion mutations, says Ramalingam. Moreover, the median progression-free survival in this cohort was 7.3 months, and the median overall survival was 24 months.

For a group of patients for whom there hasn’t been an effective targeted therapy until recently with the approval of amivantamab-vmjw (Rybrevant), these data are clinically meaningful, concludes Ramalingam.